CAR-T细胞治疗实体肿瘤相关肿瘤抗原的研究进展

Progress of Tumor Associated Antigen of Chimeric Antigen Receptor T Cells in Treatment for Solid Tumor

以嵌合型抗原受体（chimeric antigen receptor,CAR）为基础的细胞免疫治疗是一种新的治疗恶性肿瘤的模式,为部分晚期实体瘤患者带来治愈的希望。目前CAR-T细胞已应用于多种实体肿瘤临床试验研究,尤其是在晚期进展性肿瘤中研究广泛,选择特异性强的合适的TAA,将使CAR-T细胞造福越来越多的晚期肿瘤患者。

Cell immunotherapy based on chimeric antigen receptor（CAR） is a new treatment for malignant tumors, and it is a promising treatment for patients with advanced solid tumors. At present, CAR-T cells have been used in clinical trials of many solid tumors,especially in advanced tumors. A wide range of tumor associated antigens （TAA） have been found. The selection of a strong specificity and appropriate TAA in treatment of CAR-T will benefit more and more advanced cancer patients.